Recent News

• 06.13.2025 - UroGen Pharma ZUSDURI Approval Investor Call
• 06.13.2025 - UroGen Pharma ZUSDURI Approval Investor Call
• 06.12.2025 - U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
• 06.12.2025 - U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
• 06.06.2025 - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.02.2025 - UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
• 06.02.2025 - UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
• 06.02.2025 - UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
• 06.02.2025 - UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
• 05.28.2025 - TD Cowen

Recent Filings

• 06.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 144 Report of proposed sale of securities
• 06.09.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors